| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/31/2002 | US20020012931 High specificity marker detection |
| 01/31/2002 | US20020012919 Nucleic acids of rochalimaea henselae and methods and compositions for diagnosing rochalimaea henselae and rochalimaea quintana infection |
| 01/31/2002 | US20020012696 In gene therapy and in in vitro and in vivo transfection |
| 01/31/2002 | US20020012692 Activating textile carrier to form aldehyde groups, impregnating active carrier in solution bioactive enzyme and drying |
| 01/31/2002 | US20020012680 Compositions and methods for improved delivery of lipid regulating agents |
| 01/31/2002 | US20020012671 Channel forming toxins as antiviral agents |
| 01/31/2002 | US20020012669 For detecting a genetic abnormality, cancer |
| 01/31/2002 | US20020012665 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 01/31/2002 | US20020012662 Method of treating sickle cell disease or thalassemia |
| 01/31/2002 | US20020012661 Methods for introducing genes into mammalian subjects |
| 01/31/2002 | US20020012658 Prevention and treatment of verotoxin-induced disease |
| 01/31/2002 | US20020012657 Method for in vitro preconditioning of myoblasts before transplantation |
| 01/31/2002 | US20020012656 Adenoviral vectors for mutants of human interleukin 6 (hil-6) with hil-6 antagonist activity, pharmaceutical compositions therewith and their uses |
| 01/31/2002 | US20020012655 Administering to or transplanting into least one cell or tissue obtained from cloned ungulate animal or embryo for therapy |
| 01/31/2002 | US20020012651 Release of therapeutic agents in a vessel or tissue |
| 01/31/2002 | DE10035352A1 Verfahren zur Behandlung von instabiler Angina pectoris A method for the treatment of unstable angina |
| 01/31/2002 | DE10033855A1 Transdermal therapeutic system for long-term treatment of hypertension, containing dicarboxylic acid angiotensin converting enzyme inhibitor converted into salt or ester derivative to improve stability |
| 01/31/2002 | CA2797652A1 Multi-component biological transport systems |
| 01/31/2002 | CA2429502A1 Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue |
| 01/31/2002 | CA2418282A1 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/31/2002 | CA2418215A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | CA2418204A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2418199A1 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2418179A1 The protein kinase domain of the large subunit of herpes simplex type 2 ribonucleotide reductase (icp10pk) has anti-apoptopic activity |
| 01/31/2002 | CA2417508A1 Glycosylated vegf-b and method for increasing the amount of soluble vegf-b |
| 01/31/2002 | CA2417185A1 Multivalent target binding protein |
| 01/31/2002 | CA2416988A1 Leucine-based motif and clostridial neurotoxins |
| 01/31/2002 | CA2416793A1 Inhibition of lipoprotein secretion |
| 01/31/2002 | CA2416755A1 Lrp-mediated modulation of neuronal calcium influx via nmda receptors, and uses thereof |
| 01/31/2002 | CA2416751A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | CA2416750A1 Compounds having mif antagonist activity |
| 01/31/2002 | CA2416733A1 Nk cells activating receptors and their therapeutic and diagnostic uses |
| 01/31/2002 | CA2416713A1 Novel siglecs and uses thereof |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416664A1 Zinc finger domain recognition code and uses thereof |
| 01/31/2002 | CA2416657A1 Fh-binding protein of streptococcus pneumoniae |
| 01/31/2002 | CA2416643A1 Ghrelin antagonists |
| 01/31/2002 | CA2416548A1 Artificial vascular grafts, and methods of producing and using same |
| 01/31/2002 | CA2416544A1 Mu-conopeptides |
| 01/31/2002 | CA2416538A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/31/2002 | CA2416496A1 Adhesion molecules |
| 01/31/2002 | CA2416488A1 Codon-optimized papilloma virus sequences |
| 01/31/2002 | CA2416414A1 Human kinases |
| 01/31/2002 | CA2416408A1 Methods for therapy of neurodegenerative disease of the brain |
| 01/31/2002 | CA2416404A1 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 01/31/2002 | CA2416358A1 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type i interferons |
| 01/31/2002 | CA2416287A1 Omega-conopeptides |
| 01/31/2002 | CA2415345A1 Linkage of agents using microparticles |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2412544A1 Polypeptide delivery ii-2 |
| 01/31/2002 | CA2412408A1 Human tumor necrosis factor receptors tr21 and tr22 |
| 01/31/2002 | CA2410766A1 Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2410682A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2410562A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/30/2002 | EP1176201A2 Platelet-specific chimeric immunoglobulin |
| 01/30/2002 | EP1176200A2 Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases or wound healing and their use in indentifying pharmacologically acitve substances |
| 01/30/2002 | EP1176199A1 Tumor suppressor genes |
| 01/30/2002 | EP1176198A1 Novel fetal genes |
| 01/30/2002 | EP1176193A1 Inhibitors for viral infection targeting integrase n-terminal region |
| 01/30/2002 | EP1176192A2 Helicobacter felis vaccine |
| 01/30/2002 | EP1176154A1 Carnosine derivatives, a process for the preparation thereof and pharmaceutical compositions containing them |
| 01/30/2002 | EP1175912A1 Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| 01/30/2002 | EP1175911A2 Uses of recombinant colony stimulating factor-1 for treatment of leukopenia |
| 01/30/2002 | EP1175910A2 Methods and compounds for prevention of graft rejection |
| 01/30/2002 | EP1175909A2 Therapeutic methods and compositions based on serrate proteins and nucleic acids |
| 01/30/2002 | EP1175900A2 Use of growth hormone secretagogues for improvement of fucnctional health status |
| 01/30/2002 | EP1175839A2 Antimicrobial agent against acid-resistant and heat-resistant bacteria |
| 01/30/2002 | EP1175616A1 Methods for the diagnosis and treatment of metastatic prostate tumors |
| 01/30/2002 | EP1175513A1 MinK-RELATED GENES, FORMATION OF POTASSIUM CHANNELS AND ASSOCIATION WITH CARDIAC ARRHYTHMIA |
| 01/30/2002 | EP1175503A1 49 human secreted proteins |
| 01/30/2002 | EP1175497A2 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| 01/30/2002 | EP1175492A1 Star homologues |
| 01/30/2002 | EP1175491A1 Recombinant protein uk114 and its use in therapy and diagnostics |
| 01/30/2002 | EP1175488A1 Cosmetic or pharmaceutical composition useful in inhibiting or delaying human alopecia by means of topical application of the composition |
| 01/30/2002 | EP1175453A2 Differentially acting op detoxifying sponges |
| 01/30/2002 | EP1175444A1 Amino-terminal modified parathyroid hormone (pth) analogs |
| 01/30/2002 | EP1175443A1 Modified exendins and exendin agonists |
| 01/30/2002 | EP1175442A2 Osteopontin-derived chemotactic and inhibitory agents and uses therefor |
| 01/30/2002 | EP1175441A1 Neurite outgrowth and guidance by tenascin-c |
| 01/30/2002 | EP1175440A1 48 human secreted proteins |
| 01/30/2002 | EP1175439A1 49 human secreted proteins |
| 01/30/2002 | EP1175438A1 62 human secreted proteins |
| 01/30/2002 | EP1175435A1 Cephaibols, novel antiparasitics from acremonium tubakii, method for the production and the utilization thereof |
| 01/30/2002 | EP1175405A1 LACTAM INHIBITORS OF FXa AND METHOD |
| 01/30/2002 | EP1175390A1 Disodium salts, monohydrates, and ethanol solvates |
| 01/30/2002 | EP1175235A1 Modified protein matrices |
| 01/30/2002 | EP1175228A1 Gene therapy using tgf-beta |
| 01/30/2002 | EP1175225A2 Elastin-based compositions |
| 01/30/2002 | EP1175224A2 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 01/30/2002 | EP1175223A2 Methods and compositions for modulating an immune response |
| 01/30/2002 | EP1175222A2 Monthly doses of glycopeptide antibiotics for treatment of streptococcus pneumoniae infections |
| 01/30/2002 | EP1175218A1 Ocular therapy in keratoconjuctivitis sicca using topically applied androgens or tgf-beta |
| 01/30/2002 | EP1175144A2 Orally immunogenic bacterial enterotoxins expressed in transgenic plants |
| 01/30/2002 | EP0904539A4 Inhibiting protein interactions |
| 01/30/2002 | EP0904284B1 6-substituted amino-4-oxa-1-azabicyclo[3.2.0]heptan-7-one derivatives as cysteine protease inhibitors |
| 01/30/2002 | EP0888373A4 Smooth muscle cell lim protein |
| 01/30/2002 | EP0857060B1 Method and preparations for stabilizing biological materials by drying methods without freezing |
| 01/30/2002 | EP0832198A4 Oxygen activatable formulations for disinfection or sterilization |
| 01/30/2002 | EP0819136B1 Mdp derivatives and conjugates having haematopoietic function stimulating activity, and compositions containing same |